Skip to Content

GaviLyte-N (polyethylene glycol 3350 with electrolytes) Disease Interactions

There are 7 disease interactions with GaviLyte-N (polyethylene glycol 3350 with electrolytes):

Major

Laxatives (Includes GaviLyte-N) ↔ inflammatory bowel disease

Severe Potential Hazard, Moderate plausibility. Applies to: Inflammatory Bowel Disease

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (Includes GaviLyte-N) ↔ intestinal obstruction disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
View all 5 references
Major

PEG solutions (Includes GaviLyte-N) ↔ GI obstruction/perforation

Severe Potential Hazard, High plausibility. Applies to: Gastrointestinal Obstruction, Gastrointestinal Perforation, Ulcerative Colitis

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.

References

  1. Raymond PL "Mallory-Weiss tear associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 37 (1991): 410-1
  2. "Product Information. Golytely (polyethylene glycol electrolyte solution)." Braintree, Braintree, MA.
  3. McBride MA, Vanagunas A "Esophageal perforation associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 39 (1993): 856-7
Moderate

PEG electrolyte solutions (Includes GaviLyte-N) ↔ arrhythmias

Moderate Potential Hazard, Moderate plausibility. Applies to: Heart Disease

The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias. Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.

Moderate

PEG electrolyte solutions (Includes GaviLyte-N) ↔ impaired gag reflex

Moderate Potential Hazard, Moderate plausibility. Applies to: Esophageal Obstruction

Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously. Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.

References

  1. "Product Information. Golytely (polyethylene glycol electrolyte solution)." Braintree, Braintree, MA.
Moderate

PEG electrolyte solutions (Includes GaviLyte-N) ↔ renal disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Dehydration

Use caution when prescribing PEG electrolyte solutions to patients with impaired renal function or patients taking concomitant medications that may affect renal function. Ensure adequate hydration and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

Moderate

PEG electrolyte solutions (Includes GaviLyte-N) ↔ seizures

Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures, Hyponatremia

PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness. The seizure cases were associated with electrolyte abnormalities and low serum osmolality. Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.

GaviLyte-N (polyethylene glycol 3350 with electrolytes) drug interactions

There are 664 drug interactions with GaviLyte-N (polyethylene glycol 3350 with electrolytes)

GaviLyte-N (polyethylene glycol 3350 with electrolytes) alcohol/food interactions

There is 1 alcohol/food interaction with GaviLyte-N (polyethylene glycol 3350 with electrolytes)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide